Single Measures of Viral Load May Overestimate HIV Suppression

Share this content:
Single Measures of Viral Load May Overestimate HIV Suppression
Single Measures of Viral Load May Overestimate HIV Suppression

MONDAY, Aug. 7, 2017 (HealthDay News) -- Single measures of viral load can overestimate how many individuals with HIV infection have viral suppression, according to an observation piece published online Aug. 8 in the Annals of Internal Medicine.

Nicole Crepaz, Ph.D., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues used data reported to the National HIV Surveillance System from 33 jurisdictions and calculated the percentage of persons with HIV infection whose last viral load in 2014 was less than 200 copies/mL.

The researchers found that the median time from diagnosis to the end of 2013 was 11 years; in 2014, viral load was measured a median of two times. Overall, 57.3 percent of persons with HIV infection had a suppressed viral load on their most recent test in 2014, 47.6 percent had durable viral suppression throughout 2014, and viral suppression was never achieved by 8.1 percent. Women, black persons/African-Americans, younger persons, and persons with HIV infection from causes other than male-to-male sexual contact were more likely not to have viral suppression on their most recent viral load test or durable viral suppression. Overall, 56.3 percent of the 51,114 persons who never achieved viral suppression in 2014 had at least two tests for viral load that year.

"These findings emphasize the importance of routine monitoring of viral suppression status and of more effective delivery of appropriate therapy in response to the results of such monitoring," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Cost-Effectiveness of PCSK9 Inhibitors Called Into Question

Cost-Effectiveness of PCSK9 Inhibitors Called Into Question

Researchers say price would have to be between $4,000 and $5,000 per year to be cost-effective

Vitamin B6, B12 Supplements May Up Risk of Lung Cancer in Men

Vitamin B6, B12 Supplements May Up Risk of ...

Increased odds only seemed to affect men or male smokers

Tablet Use Encourages Patients to Explore Diabetes Risk

Tablet Use Encourages Patients to Explore Diabetes Risk

Replacing magazines with tablets can help patients learn about diabetes risk, take preventive action

is free, fast, and customized just for you!

Already a member?

Sign In Now »